Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0298775 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Zhangxin Ji und 7 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, Anhui, PR China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Anhui Provincial Department of Education, University Natural Science Research Project of Anhui Province, State Key Laboratory of Tea Plant Biology and Utilization.
Abstract (Originalsprache)
Background
Activated neutrophils release depolymerized chromatin and protein particles into the extracellular space, forming reticular Neutrophil Extracellular Traps (NETs). This process is accompanied by programmed inflammatory cell death of neutrophils, known as NETosis. Previous reports have demonstrated that NETosis plays a significant role in immune resistance and microenvironmental regulation in cancer. This study sought to characterize the function and molecular mechanism of NETosis-correlated long non-coding RNAs (NCLs) in the prognostic treatment of liver hepatocellular carcinoma (LIHC).
Methods
We obtained the transcriptomic and clinical data from The Cancer Genome Atlas (TCGA) and evaluated the expression of NCLs in LIHC. A prognostic signature of NCLs was constructed using Cox and Last Absolute Shrinkage and Selection Operator (Lasso) regression, while the accuracy of model was validated by the ROC curves and nomogram, etc. In addition, we analyzed the associations between NCLs and oncogenic mutation, immune infiltration and evasion. Finally, LIHC patients were classified into four subgroups based on consensus cluster analysis, and drug sensitivity was predicted.
Results
After screening, we established a risk model combining 5 hub-NCLs and demonstrated its reliability. Independence checks suggest that the model may serve as an independent predictor of LIHC prognosis. Enrichment analysis revealed a concentration of immune-related pathways in the high-risk group. Immune infiltration indicates that immunotherapy could be more effective in the low-risk group. Upon consistent cluster analysis, cluster subgroup 4 presented a better prognosis. Sensitivity tests showed the distinctions in therapeutic effectiveness among various drugs in different subgroups.
Conclusion
Overall, we have developed a prognostic signature that can discriminate different LIHC subgroups through the 5 selected NCLs, with the objective of providing LIHC patients a more precise, personalized treatment regimen.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Xin'an Medicine, Ministry of Education, Anhui University of Chinese Medicine, Hefei, Anhui, PR China.
- School of Graduate, Anhui University of Chinese Medicine, Hefei, Anhui, PR China.
- Research and Technology Center, Anhui University of Chinese Medicine, Hefei, Anhui, PR China.
- State Key Laboratory of Tea Plant Biology and Utilization, School of Tea & Food Science and International Joint Laboratory on Tea Chemistry and Health Effects of Ministry of Education, Anhui Agricultural University, Hef…
- Institute of Surgery, Anhui Academy of Chinese Medicine, Anhui University of Chinese Medicine, Hefei, Anhui, PR China.
ORCID-Profile: Jun Chu
Förderung
- Anhui Provincial Department of Education
- University Natural Science Research Project of Anhui Province
- State Key Laboratory of Tea Plant Biology and Utilization
Zitieren
APA
Ji, Z., Zhang, C., Yuan, J., He, Q., Zhang, X., Yang, D., Xu, N., & Chu, J. (2024). Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma. PLOS ONE. https://doi.org/10.1371/journal.pone.0298775
Vancouver
Ji Z, Zhang C, Yuan J, He Q, Zhang X, Yang D, et al. Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma. PLOS ONE. 2024. doi:10.1371/journal.pone.0298775
BibTeX
@article{Ji2024,
author = {Ji, Zhangxin and Zhang, Chenxu and Yuan, Jingjing and He, Qing and Zhang, Xinyu and Yang, Dongmei and Xu, Na and Chu, Jun},
title = {Predicting the immunity landscape and prognosis with an NCLs signature in liver hepatocellular carcinoma},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0298775}
}
EUVIMED